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Abstract The site-specific recombination system of bacterio-
phage P1 is composed of the Cre recombinase that recognizes a
34-bp loxP site. The Cre/loxP system has been extensively used
to manipulate eukaryotic genomes for functional genomic
investigations. The creation of additional heterologous loxP
sequences potentially expands the utility of this system, but only
if these loxP sequences do not recombine with one another. We
have developed a stringent in vivo assay to examine the degree of
recombination between all combinations of each previously
published heterologous loxP sequence. As expected, homologous
loxP sequences efficiently underwent Cre-mediated recombina-
tion. However, many of the heterologous loxP pairs were able to
support recombination with rates varying from 5 to 100%. Some
of these loxP sequences have previously been reported to be non-
compatible with one another. Our study also confirmed other
heterologous loxP pairs that had previously been shown to be
non-compatible, as well as defined additional combinations that
could be used in designing new recombination vectors. ß 2001
Federation of European Biochemical Societies. Published by
Elsevier Science B.V. All rights reserved.
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1. Introduction
Bacteriophage P1 contains a site-speci¢c recombination sys-
tem responsible for genome partitioning after replication [1].
This system is composed of a 38-kDa Cre recombinase which
mediates recombination between two 34-bp loxP sites and
does not require any accessory factors. The loxP site contains
two 13-bp inverted repeats £anking an asymmetric 8-bp core
region that gives the loxP site an apparent directionality. Cre-
mediated recombination between two aligned loxP sites will
excise the intervening DNA, while recombination between in-
verted loxP sites should result in the inversion of that same
DNA [2]. Crystal structures reveal that each 13-bp inverted
repeat is individually bound by a Cre monomer and recombi-
nation involves the formation of a Holliday junction [3,4].
Strand exchange begins after single-strand (ss) nicks are pro-
duced at a speci¢c site within each 8-bp core by conserved
tyrosines on two Cre subunits, generating nucleophiles that
complete the exchange of one set of strands. The Holliday
intermediate is resolved to the recombinant products after
cleavage and exchange of the remaining pair of DNA strands
by the second pair of Cre subunits.
The Cre/loxP recombination system has proven to be an
important tool for in vivo manipulation of eukaryotic ge-
nomes [5,6]. Gene activation and deactivation strategies in
mammalian cells [7^10] and transgenic mice [11^13] have
been developed by expressing Cre in a temporally and/or spa-
tially controlled fashion. However, further exploitation of this
system has been limited by the availability of only one loxP
sequence. To this end, studies have identi¢ed hetero-speci¢c
loxP sequences that recombine e⁄ciently with the identical
loxP mutant and not with the original wild-type (WT) loxP
sequence (see Fig. 1): 511 loxP contains a C to T transition at
position 2 of the core region [14], 2272 loxP contains a C to G
transversion at position 2 and an A to C transversion at
position 7 [15], 5171 loxP contains a C to T transition at
position 2 and a T to C transition at position 4 [15], and
FAS loxP is a naturally occurring sequence near the FAS1
gene in Saccharomyces cerevisiae [16]. The combination of
WT loxP and 511 loxP has been successfully used for a dou-
ble-reciprocal crossover reaction to transfer a DNA segment
or gene to a predetermined target site [7,17,18] and has facili-
tated the creation of phagemid antibody libraries [19,20]. Re-
cent reports, however, have suggested recombination can oc-
cur between WT and 511 loxP sequences [7,15].
In order to expand the utility of the Cre/loxP system for
future functional genomic studies and to verify that each loxP
sequence does not recombine with any other published loxP
sequence, we devised an assay to study recombination be-
tween all possible combinations of the ¢ve heterologous
loxP sites in vivo. Results show that when homologous loxP
sequences are present, recombination occurs at nearly 100%
for all ¢ve sequences. However, one third of the chimeric
constructs containing di¡erent loxP sequences were able to
support recombination above 5%, with one heterologous
pair nearly 100% e⁄cient. We also observed di¡erences in
recombination rates between di¡erent loxP sequences depend-
ing on their relative orientation to one another. These results
impact the design of recombination vectors in which more
than one loxP sequence is used.
2. Materials and methods
2.1. Bacterial strains
DH5KFP (Gibco BRL, Rockville, MD, USA): FP/endA1 hsdR17
(rK-mK) supE44 thi-1 recA1 gyrA (Na1r) relA1 v (lacZYA-argF)
U169 deoR (x80dlacv(lacZ)M15).
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BS1365 (kind gift from Dr. Brian Sauer): BS591 FP kan (BS591:
recA1 endA1 gyrA96 thi-1 v lacU169 supE44 hsdR17 [lambda imm434
nin5 X1-cre]).
2.2. LoxP/green £uorescent protein (GFP) constructs
GFP [21] was ampli¢ed with primers (see Section 2.3) that ap-
pended appropriate loxP sites 5P and 3P of the GFP encoding se-
quence. The primers incorporated di¡erent restriction sites 5P to
each loxP sequence for identi¢cation, as well as the restriction sites
used for cloning (HindIII and EcoRI) (see Figs. 1 and 2). In addition,
the 3P primers inserted a stop codon immediately after the GFP en-
coding sequence. The loxP sequences (except for 511-I loxP) are ori-
entated such that potential ATG start sites are located on the opposite
strand. The PCR products were cloned into the multiple cloning site
of pUC119 (ATCC # 37461) inactivating the alpha peptide fragment
of L-galactosidase (lacZP), but leaving the start codon of lacZP in
frame with GFP, allowing translation of GFP upon induction with
isopropyl-1-thio-L-D-galactoside (IPTG). This construct also contains
both the M13 origin of replication, allowing incorporation into ¢la-
mentous phagemid particles in the presence of M13K07 helper phage
(NEB, Beverly, MA, USA), and the colE1 origin of replication, al-
lowing double-strand (ds) DNA to be ampli¢ed. The loxP/GFP plas-
mids were transfected into DH5KFP cells and £uorescent colonies
containing the appropriate loxP sites, as determined by restriction
digests, were used to generate phagemid after helper phage infection
as described [22]. LoxP/GFP constructs that have not had an oppor-
tunity to recombine are denoted as 1‡ while constructs that have had
an opportunity to recombine are denoted as 2‡ (see Section 2.4).
2.3. Primers
WT loxP/GFP-5P : CCC AAG CTT CGC TAG CAT AAC TTC
GTA TAG CAT ACA TTA TAC GAA GTT ATC CAT GAG
TAA AGG AGA AGA ACT T
WT loxP/GFP-3P : GGA ATT CGC TAG CGA TAA CTT CGT
ATA ATG TAT GCT ATA CGA AGT TAT TTG TAT AGT
TCA TCC ATG CC
511 loxP/GFP-5P : CCC AAG CTT CCT GCA GAT AAC TTC
GTA TAG TAT ACA TTA TAC GAA GTT ATC CAT GAG
CAA AGG
511 loxP/GFP-3P : GGA ATT CCT GCA GGA TAA CTT CGT
ATA ATG TAT ACT ATA CGA AGT TAT TTG TAG AGC
TCA TCC
511-I loxP/GFP-5P : CCC AAG CTT CGG ATC CAT AAC TTC
GTA TAA TGT ATA CTA TAC GAA GTT ATC CAT GAG
TAA AGG
511-I loxP/GFP-3P : GGA ATT CGG ATC CGA TAA CTT CGT
ATA GTA TAC ATT ATA CGA AGT TAT TTG TAT AGT
TCA TCC
2272 loxP/GFP-5P : CCC AAG CTT CAG ATC TAT AAC TTC
GTA TAG GAT ACC TTA TAC GAA GTT ATC CAT GAG
TAA AGG
2272 loxP/GFP-3P : GGA ATT CAG ATC TGA TAA CTT CGT
ATA AGG TAT CCT ATA CGA AGT TAT TTG TAT AGT
TCA TCC
5171 loxP/GFP-5P : CCC AAG CTT CCC GCG GAT AAC TTC
GTA TAG TAC ACA TTA TAC GAA GTT ATC CAT GAG
TAA AGG
5171 loxP/GFP-3P : GGA ATT CCC GCG GGA TAA CTT CGT
ATA ATG TGT ACT ATA CGA AGT TAT TTG TAT AGT
TCA TCC
FAS loxP/GFP-5P : CCC AAG CTT CAC GCG TAC AAC TTC
GTA TAT ACC TTT CTA TAC GAA GTT GTC CAT GAG
TAA AGG
FAS loxP/GFP-3P : GGA ATT CAC GCG TGA CAA CTT CGT
ATA GAA AGG TAT ATA CGA AGT TGT TAT TTG TAT
AGT TCA TCC
2.4. Cre in vivo recombination assay
BS1365 cells (constitutively expressing Cre recombinase) were
grown to an OD600 of 0.5 at 37‡C and infected with loxP/GFP 1‡
phagemid. Infected cells were allowed to recombine overnight at 37‡C
in the presence of ampicillin. An aliquot of the overnight culture that
had undergone recombination was diluted and grown to midlog at
37‡C and then infected with M13K07 helper phage. Cells were then
grown overnight at 37‡C with ampicillin and kanamycin in order to
harvest loxP/GFP 2‡ phagemid. Recombination was detected by in-
fecting DH5KFP cells at OD600 of 0.5 with the various loxP/GFP 2‡
phagemids. The cells were plated on 2UYT agar containing 100 Wg/ml
ampicillin, 1 mM IPTG and 20 Wg/ml 5-bromo-4-chloro-3-indolyl-L-D-
galactoside (X-gal) at dilutions that allowed individual colonies to be
counted. 2‡ transductions into DHKFP were performed to avoid pos-
sible heterogeneity from the recombination reactions and to utilize
alpha complementation of lacZP which is not possible with BS1365.
In addition, the 511-I/511 loxP/GFP and WT/511 loxP/GFP
dsDNA 1‡ constructs were transfected into BS1365 and grown in
1 ml of 2UYT containing 100 Wg/ml ampicillin overnight at 37‡C.
The loxP/GFP 2‡ dsDNA was isolated using Qiagen spin columns
(Qiagen, Valencia, CA, USA) and then used to transfect DH5KFP
cells and plated on 2UYT agar containing 100 Wg/ml ampicillin,
1 mM IPTG and 20 Wg/ml X-gal.
The resulting 2‡ colonies from either phagemid transduction or
dsDNA transfection were visualized after excitation at 488 nm. Re-
combination that excised GFP gave blue, non-£uorescent colonies.
Recombination that inverted GFP resulted in white, non-£uorescent
colonies and was con¢rmed by diagnostic PCR. Colonies containing
phagemid DNA that did not recombine were white and £uorescent
after excitation at 488 nm. For 511-1/511, both excision and inversion
rates were used to calculate the overall recombination percentage for a
given pair of loxP sites (Table 1). Values shown are the averages of at
least three independent trials with standard deviations indicated.
3. Results
An in vivo assay was developed to test the level of recom-
bination between the ¢ve published loxP sequences in a pro-
karyotic system (Fig. 1). GFP £anked by either homologous
or heterologous loxP sites was cloned into and disrupted the
frame of the lacZP reporter gene (Fig. 2). Removal of the GFP
by Cre-mediated recombination will leave a single loxP site
and allow the lacZP fragment to be translated. Therefore,
colonies containing DNA that had not undergone recombina-
tion will remain white in the presence of X-gal and show
£uorescence after excitation at 488 nm (Fig. 2A,B, top),
whereas colonies in which recombination has excised GFP
will be blue and non-£uorescent (Fig. 2A, bottom), and col-
onies in which recombination has inverted GFP will produce
white colonies which are non-£uorescent (Fig. 2B, bottom).
Constructs are named according to the loxP sequence present
5P and 3P of GFP; e.g. WT loxP/GFP contains the WT loxP
sequence at both locations while WT/511 loxP/GFP has the
WT loxP sequence at the 5P site and the 511 loxP sequence at
the 3P site. In all, 21 combinations were constructed that
paired the ¢ve loxP sequences with one another, as well as
an inverted 511 loxP sequence (511-I). All constructs were
veri¢ed by restriction analysis using the enzymes indicated
Fig. 1. LoxP sequences. The sequence of each loxP tested is shown
and labeled on the left. 511-I loxP contains an inverted core region
sequence compared to the 511 loxP orientation. The 13-bp inverted
repeats are underlined with the 8-bp asymmetric core region num-
bered with potential ATG start sites located on the bottom, non-
coding strand (except for 511-I). The restriction site used to identify
each loxP sequence is in parentheses to the right of the respective
sequence. The FAS loxP sequence contains one pair of recombina-
torial neutral mutations in the 13-bp inverted repeats [24].
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in Fig. 1 (data not shown). Filamentous phagemids containing
each construct were then individually transduced into BS1365.
Phagemid particles containing loxP/GFP DNA were then pro-
duced from the Cre cells after recombination and used to
transduce DH5KFP in order to observe the recombinatorial
outcome. LoxP/GFP constructs that have not had the oppor-
tunity to recombine are denoted 1‡ and constructs that have
been passaged through BS1365 are denoted 2‡.
As a test of our in vivo Cre recombination system, we
transduced either DH5KFP or BS1365 with WT loxP/GFP
1‡ phagemid. Transduced cells were allowed to ‘recombine’
overnight in the presence (BS1365) or absence (DH5KFP) of
Cre recombinase before 2‡ phagemids were produced. The 2‡
phagemids from both strains were then separately transduced
into DH5KFP (Fig. 3A). The pair of plates on the left show
that an insigni¢cant amount of recombination occurs in the
Fig. 2. Cre recombination assay. GFP (light gray box) £anked by the 5P and 3P loxP sites (solid arrows showing the directionality of the 8-bp
core sequence) was cloned into the pUC1119 polylinker disrupting the translation of the lacZP fragment (dark gray box). The lac promoter is
designated with an angled arrow and the expected translation product is shown as an open arrow beneath. The 2‡ colony phenotype is shown
to the right of the translated product. A: Excision recombination product. Cre recombination between compatible loxP sites excises the GFP
gene (dashed lines) and allows the lacZP fragment to be translated from the lac promoter. B: Inversion recombination product. Cre recombina-
tion between inverted loxP sites inverts the GFP gene (dashed lines), but still does not allow translation of the lacZP fragment as a stop codon
in frame with the lac promoter is located 131 nucleotides into the reverse complement of GFP.
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absence of the Cre recombinase while the pair of plates to the
right demonstrate virtually complete recombination with the
same construct in the presence of Cre. The ability to observe
the one blue (DH5KFP, Fig. 3A, arrow far left plate) and one
£uorescent colonies (BS1365, Fig. 3A, arrow far right plate)
demonstrates the high level of sensitivity of our in vivo sys-
tem.
Having demonstrated that our system is capable of detect-
ing recombination events and that recombination is mediated
solely by Cre recombinase, we examined the recombination
rates of all the loxP/GFP constructs. Representative 2‡ colo-
nies are shown in Fig. 3B^E and Table 1 shows the level of
recombination observed for all of the constructs tested. As
expected, constructs containing the same loxP sequences 5P
and 3P of GFP e⁄ciently underwent Cre-mediated recombi-
nation (s 99%). Evaluating the degree of recombination be-
tween WT loxP with the other loxP sequences reveals that
some combinations are compatible with one another to vary-
ing extents (Table 1, WT column). For example, WT loxP and
511 loxP recombined at a level of approximately 10% (Fig.
3B), while WT loxP and the inverted orientation of 511, 511-I
loxP, recombined at the much reduced level of 1.4% (Fig. 3C).
Additionally, WT loxP paired with 5171 loxP gave a recom-
bination rate of nearly 6%. A negligible amount of recombi-
nation was observed between WT loxP and either FAS loxP
or 2272 loxP. The remaining loxP constructs also identi¢ed
several additional pairs of sequences that could recombine
with one another. The only heterologous sequence (other
than WT loxP) which 511-I was unable to recombine with
was 2272 loxP (Table 1, 511-I column). Once again, the rel-
Fig. 3. Representative recombination results. A: 2‡ colonies containing WT loxP/GFP that were originally transduced into either DH5KFP (left)
that do not or BS1365 (right) that do express Cre recombinase for the 1‡ infection. Arrows mark the one blue and one £uorescent colonies
that resulted from DH5KFP or BS1365 incubations, respectively. 2‡ colonies obtained with (B) WT/511 loxP/GFP, (C) WT/511-I loxP/GFP,
(D) 511-I/FAS loxP/GFP or (E) 511/FAS loxP/GFP that were allowed to recombine in BS1365. The left side of each panel is the 2‡ plate in
normal light and the right side is the same plate after excitation at 488 nm.
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ative orientation of 511 loxP appeared to in£uence whether
recombination could occur in some cases. Thus, FAS loxP
could recombine with 511-I loxP at approximately 6% (Fig.
3D), but was unable to recombine when 511 loxP was used
instead (Fig. 3E). However, 2272 loxP recombined with both
511-I and 511 loxP at minimal levels (6 2%), while recombi-
nation was above 50% for both when paired with 5171 loxP.
Of the remaining heterologous loxP constructs, only FAS
loxP paired with 5171 loxP gave a detectable recombination
rate of roughly 5% (Table 1, FAS column).
As a ¢nal test, we also determined the level of recombina-
tion between 511-I loxP and 511 loxP. The loxP sequences in
this construct are identical to one another but are inversely
orientated, which should give rise to an e⁄cient inversion
reaction during Cre-mediated recombination (Fig. 2B) [2].
As indicated in Table 1, overall recombination occurred at a
relatively high level of 75%. However, excised recombination
products were observed in addition to the expected inverted
products (Fig. 4A, blue and non-£uorescent, white colonies,
respectively). Excision occurred at a rate of 43 þ 8% and in-
version at a rate of 32 þ 6%. Restriction analysis was done to
verify that the 2‡ DNA was derived from the 511-I/511 loxP/
GFP 1‡ construct and that each type of 2‡ colony contained
the expected recombination product as indicated by its phe-
notype on the plate (data not shown).
The probability that these results were, in part, due to the
Table 1
LoxP recombination summary
3P lox site 5P lox site
WT 511-I 511 FAS 2272 5171
WT 99.6 ( þ 0.7)
511-I 1.4 ( þ 1.6) 99.2 ( þ 1.9)
511 10.3 ( þ 1.4) *75.3 ( þ 9.3) 99.8 ( þ 0.3)
FAS 0.2 ( þ 0.3) 5.7 ( þ 3.1) 0.0 ( þ 0.0) 99.4 ( þ 0.3)
2272 0.5 ( þ 0.4) 0.3 ( þ 0.4) 1.6 ( þ 0.3) 1.7 ( þ 0.8) 99.7 ( þ 0.5)
5171 5.7 ( þ 2.7) 77.7 ( þ 5.1) 99.9 ( þ 0.1) 4.8 ( þ 0.8) 0.1 ( þ 0.1) 99.5 ( þ 0.9)
The 5P loxP sequence is indicated on the top row and the 3P loxP sequence on the left column. The mean of at least three independent trials is
shown with the standard deviation in parentheses. The asterisk denotes recombination rates from both excision and inversion events.
Fig. 4. 511-I/511 loxP/GFP recombination. 2‡ colonies obtained after (A) phagemid transduction or (B) dsDNA transfection into BS1365. The
left side of each panel is the 2‡ plate in normal light and the right side is the same plate after excitation at 488 nm.
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use of phagemid (and its ssDNA component) was examined
by using transfection rather than transduction to deliver the
loxP/GFP constructs into bacterial cells. The 511-I/511 loxP/
GFP 1‡ dsDNA was transfected into BS1365 cells and the
puri¢ed 2‡ dsDNA was used to transfect DH5KFP cells. Sim-
ilar results to those with transductions were obtained (Fig.
4B); that is, overall recombination was e⁄cient (59 þ 2%)
with both excision (24 þ 2%) and inversion (34 þ 3%) products
present. We also determined that the growth rates of cells
containing the excised, inverted, or normal GFP constructs
were identical (data not shown).
4. Discussion
We have developed an in vivo system to determine the
degree of recombination between the ¢ve published heterolo-
gous loxP sequences. When the same loxP sequence was
present at both sites, recombination was greater than 99%
for each homologous pair (Table 1) and was dependent
upon Cre recombinase (Fig. 3A). Our results show that not
only was recombination between many of the di¡erent loxP
sequences possible (Table 1), but that the relative orientation
of the sequences also seemed to determine if recombination
could occur (Table 1, 511-I vs. 511 columns and Fig. 3B^E).
In the case of the 511-I/511 loxP/GFP construct, excision in
addition to the expected inversion reaction product was ob-
served (Fig. 4A). This excision, however, was not due to
ssDNA present during the transductions used to introduce
the constructs into the Cre expressing cells since transfection
gave similar results (Fig. 4B). A phagemid system was chosen
for this study as it closely mimics current methods used to
create very large phagemid antibody libraries [19,20] and iden-
ti¢cation of non-compatible loxP sequences is a prerequisite
to maintaining diversity within these libraries.
Our results agree with other published studies that indicate
that WT/FAS, WT/2272 and 2272/5171 pairings are non-com-
patible [15,16]. In addition, we also identify other sets of non-
compatible loxP sites that could be used together (Table 1).
Among the heterologous loxP pairings that had not been
previously characterized, the most striking is the degree of
recombination between either orientation of 511 loxP and
5171 loxP (78% and 100% for 511-I and 511, respectively).
However, it is unclear as to why no inversion reactions were
detected between 511-I and 5171 loxP sequences (data not
shown). It is intriguing to speculate whether the sequence
conservation at positions 2, 5, and 7 of the 8-bp core region
in each of these di¡erent loxP sequences somehow facilitates
this excision reaction (Fig. 1). We also observed recombina-
tion between WT loxP and 5171 loxP (6%), which had pre-
viously been reported to be non-compatible with one another
[15].
Our results also di¡er in some respects to previous studies
that have examined recombination between the WT and 511
loxP sequences. For example, Hoess et al. did not observe
recombination between WT loxP and 511 loxP [14]. In con-
trast, two other studies both reported a low degree of recom-
bination between these two heterologous sequences [7,15]. The
in vivo results presented here support those previous ¢ndings
that WT loxP can recombine with 511 loxP to a limited, but
measurable degree. The cross-reactivity between WT loxP and
511 loxP that we observed was not due to the use of phagemid
since the same level of heterologous recombination was ob-
tained after transfections (data not shown). Other reports
have used the WT loxP/511 loxP heterologous pairing to fa-
cilitate a double-crossover recombination reaction. These
studies used either the inverted orientation of 511 loxP [17],
which we show allows a very low level of recombination with
WT loxP, or were simply screening for the emergence of a
new cell line after gene replacement using transient Cre re-
combinase expression [18], in which unexpected recombina-
tion would not be seen. The combination of WT loxP and
511 loxP has also been used to generate large phagemid anti-
body libraries in a recombinatorial fashion: one used the 511-
I loxP orientation [20], while the other used 511 loxP and has
displayed some background level of deletions [19], although it
is unclear whether these deletions are due to heterologous
recombination between the loxP sites or spontaneous eviction
from the ssDNA phage genome.
Many possibilities could account for the apparent dispar-
ities between the results presented in this work with those
obtained in other studies. The format of our experiments
has allowed us to examine thousands of di¡erent recombina-
tion events for each pair of loxP sites. In this respect, our
results di¡er from those previously reported which have
tended to look only for speci¢c events in small trial numbers.
Additionally and perhaps more importantly, by carrying out
prolonged incubations of the loxP/GFP constructs in cells
containing high concentrations of the Cre recombinase, our
experiments represent a very stringent examination of lox site
compatibility which probably ampli¢es low levels of recombi-
nation occurring between disparate sequences in the absence
of strict sequence homology. This possibility is supported by a
recent report demonstrating that persistent high-level Cre ex-
pression leads to gross chromosomal rearrangements in the
absence of exogenous loxP sites [23]. Therefore, it is possible
that the heterologous pairs of loxP sequences, that we dem-
onstrate are capable of very low levels of recombination,
might not have been observed in previous studies. Our assay,
therefore, by being more stringent, has identi¢ed those loxP
sequences that should be non-compatible with one another in
a variety of conditions for future applications. If, however,
loxP sequences which we have identi¢ed as capable of recom-
bining with one another at low levels need to be used, we
suggest limiting the time and/or amount of Cre recombinase
expression.
Given the growing importance of the Cre/loxP system for
the elucidation of gene function, more elaborate schemes to
activate or deactivate genes, as well as allowing selectable
markers to be recycled for subsequent re-use require the avail-
ability of sets of non-compatible loxP sites. Integrating multi-
ple non-compatible loxP sites into a genome at de¢ned loca-
tions allows the subsequent Cre-mediated introduction of a
transgene construct to di¡erent chromosomal locations by
simply specifying the corresponding loxP sites on the targeting
vector. The expanded utility of these techniques and the cre-
ation of multiple targeting vectors can have a tremendous
impact on the growing ¢eld of functional genomics. Our study
identi¢es several pairs of non-compatible heterologous loxP
sequences that can be used to create di¡erent targeting vectors
containing two or more loxP sites for manipulation.
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